
Bausch + Lomb's Yolande Barnard, shares an update on the FDA approval of XIPERE for the treatment of macular edema associated with uveitis.

Bausch + Lomb's Yolande Barnard, shares an update on the FDA approval of XIPERE for the treatment of macular edema associated with uveitis.

Dilsher Dhoot, MD, reports results of the KESTREL and KITE trials, in which brolucizumab was compared with aflibercept for treating diabetic macular edema.

The Academy's annual meeting set for November 12 to 15 in New Orleans.

Cataract surgeons must consider medication history as part of preoperative evaluation.

Tarsus Pharmaceuticals's CEO Bobby Azamian, MD, PhD, and Chairman Michael Ackermann, PhD, speak on the development of their company and the latest updates on their lead candidate product to treat Demodex blepharitis.

Visus Therapeutics CEO Ben Bergo shares an update on the status of its lead product candidate for presbyopia treatment as well as what's in the company's pipeline for 2021.

Thomas Samuelson, MD, speaks on the outcomes of a three-year trial analyzing the iStent inject trabecular micro-bypass + phaco versus phaco alone in patients with POAG.

Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease.

Robert Ang, MD, discusses highlights of his AAO 2020 presentation on a study analyzing the vIsual outcomes of a small-aperture IOL implantation in patients with a history of post-laser refractive surgery.

Richard Lehrer, MD, speaks on the highlights of a study analyzing the success of SLT after trabecular bypass stenting / phacoemulsification, presented during AAO 2020.

Tanner Ferguson, MD, Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting.

Daniel H. Chang, MD, speaks on the highlights of his presentation on "Violet Light-Filtering IOLs: Visual and Non-Visual Benefits," during the virtual AAO 2020 meeting.

John A. Hovanesian, MD, discusses the highlights of his presentation on a clinical study evaluating dexamethasone vs prednisolone acetate 1% in controlling postop pain/inflammation in sequential cataract surgery patients.

Michael R. Robinson, MD, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.

Ehsan Rahimy, MD, speaks on the highlights of a study he presented at this year's virtual AAO 2020 meeting that aimed to integrate an artificial intelligence screening system for managing diabetic retinopathy referrals in a primary care setting — with limited specialty support.

Davinder Grover, MD, MPH, speaks on the highlights of his presentation regarding outcomes of a 12-year study comparing ab externo vs ab interno xen gel stents in tertiary glaucoma practice.

During AAO 2020, Cathy G. Cohen, MHSA, CAE, AAO vice president for governmental affairs, offered some optimism for the future of health care under the Biden administration.

A unique Behind-the-Scenes series from the American Academy of Ophthalmology Truhlsen-Marmor Museum of the Eye kicks off November 18, from noon to 1 pm Pacific, with “The National Trachoma Service.” Register now for this event.

Robert Weinstock, MD, presents data from a retrospective multicenter study focusing on the efficacy of dexamethasone intraocular suspension 9% delivered at the time of cataract surgery.

Bradley Smith, MD, presents at AAO 2020 on how fingolimod 0.5 mg, a first-line treatment for multiple sclerosis, may reduce both the number of relapses and disease progression in patients with relapsing-remitting MS as well as the incidence of uveitis.

Speaking during the American Academy of Ophthalmology’s virtual 2020 annual meeting, Neal H. Shorstein, MD, explained how physicians at Kaiser Permanente have been using a prophylactic drop-free drug regimen before cataract surgery for more than a decade. Their regimen is so streamlined that the only drop that patients receive in anticipation of cataract surgery is a supplemental dilation drop instilled preoperatively while they are still in the holding area.

Rudy Nuijts of the University Eye Clinic Maastricht, the Netherlands, discusses the highlights of his AAO 2020 presentation on a combination treatment regimen for lowering the incidence of cystoid macular oedema following category surgery.

Cynthia Matossian, MD, FACS, ABES presents the highlights of a poster on outcomes with dexamethasone intraocular suspension 9% and concomitant postoperative anti-inflammatory medications.

Kristen Brotherson, vice president, US surgical marketing for Alcon, discusses some of the recent advances in cataract surgery-related technologies, including a new advanced lens for patients with presbyopia (AcrySof IQ Vivity IOL).

Tamer Mahmoud, MD, PhD, discusses autologous retinal transplant (ART) for macular holes, a procedure he developed, which is providing anatomic hole closure in the vast majority of cases as well as increases in visual acuity.

In a presentation at the American Academy of Ophthalmology’s virtual 2020 annual meeting, Amy K. Hutchinson, MD, explained that while Myopia has been occurring at epidemic rates worldwide, research has found that the use of orthokeratology and multifocal contact lenses can provide clinically meaningful reductions in myopia progression.

During a presentation at the American Academy of Ophthalmology’s 2020 virtual annual meeting, Kathleeen B. Digre, MD, details how a headache in conjunction with visual loss is a scenario that requires an in-depth examination, including evaluation of the visual fields, pupils, and fundus to gather clues to the diagnosis.

Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.

Ram Liebenthal, U.S. general manager for Heidelberg Engineering, discusses how the company continues to invest in the Spectralis platform in terms of hardware and software improvements.

Josh Anderson, head of U.S. retina sales and marketing for Alcon, outlines what attendees will learn including product updates, new technologies, and practice management materials for ophthalmologists and their patients during the COVID-19 pandemic.